The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), known to cause the
disease COVID-19, was declared a pandemic in early 2020. The objective of this review was …

… The anti-CoV-2 vaccines were developed in a much shorter time than previous vaccines: …
used in humans, whereas the anti-SARS-CoV-2 vaccines were ready in eight to ten months. …

… We systematically evaluated the anti-SARS-CoV-2 activities of … Arteannuin B showed the
highest anti-SARS-CoV-2 potential … step of SARS-CoV-2 infection. This research highlights the …

… This invention describes how isolated heavy- and light-chain immunoglobulins derived
from human anti-SARS-CoV's S protein antibodies and nucleic acid molecules encoding such …

… scientific community with a research reagent for an anti-SARS-CoV-2 antibody. The availability
of … for the WHO International Standards for anti-SARS-CoV-2 immunoglobulin. The study …

… a The total anti-SARS-CoV-2 IgM and IgG level of confirmed … c The prevalence of total
anti-SARS-CoV-2 IgM and IgG. The X … The increase of anti-SARS-CoV-2 antibody levels is one of …

(COVID-19) result that is incorrect (false negative) in some people with COVID-19. A negative
result may occur if you are tested during the early stages of your illness where your body …

… of qualitative anti-SARS-CoV-2 serology assays, including the qualitative Roche anti-SARS-CoV-2 …
No samples that were positive by the qualitative Roche anti-SARS-CoV-2 assay were …

… that the Elecsys Anti-SARS-CoV-2 S assay can be utilized to meet the current need for
anti-SARS-CoV-2 antibody testing, alongside or in place of the Elecsys Anti-SARS-CoV-2 (N) …

… Anti-SARS-CoV-2 immunoassay. Sensitivity and agreement between Elecsys Anti-SARS-CoV-2 …
samples from patients with PCR-confirmed SARS-CoV-2 infection, a majority of whom …